Review



rt-cgm dexcom g4  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Dexcom Inc rt-cgm dexcom g4
    Main findings and highlights resulted by the systematic review
    Rt Cgm Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rt-cgm dexcom g4/product/Dexcom Inc
    Average 90 stars, based on 1 article reviews
    rt-cgm dexcom g4 - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications"

    Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

    Journal: Reviews in Endocrine & Metabolic Disorders

    doi: 10.1007/s11154-024-09903-y

    Main findings and highlights resulted by the systematic review
    Figure Legend Snippet: Main findings and highlights resulted by the systematic review

    Techniques Used: Control

    Rt-CGM/FGM in GSDs: population features, devices and study design
    Figure Legend Snippet: Rt-CGM/FGM in GSDs: population features, devices and study design

    Techniques Used: Control

    Rt-CGM/FGM in CH: population features, devices and study design
    Figure Legend Snippet: Rt-CGM/FGM in CH: population features, devices and study design

    Techniques Used: Biomarker Discovery, Control



    Similar Products

    rt-cgm dexcom g4  (Dexcom Inc)
    90
    Dexcom Inc rt-cgm dexcom g4
    Main findings and highlights resulted by the systematic review
    Rt Cgm Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rt-cgm dexcom g4/product/Dexcom Inc
    Average 90 stars, based on 1 article reviews
    rt-cgm dexcom g4 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    rt-cgm dexcom g4 platinum system  (Dexcom Inc)
    90
    Dexcom Inc rt-cgm dexcom g4 platinum system
    Summary Results of Base Case Analysis
    Rt Cgm Dexcom G4 Platinum System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rt-cgm dexcom g4 platinum system/product/Dexcom Inc
    Average 90 stars, based on 1 article reviews
    rt-cgm dexcom g4 platinum system - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    rt-cgm dexcom g4 platinum  (Dexcom Inc)
    90
    Dexcom Inc rt-cgm dexcom g4 platinum
    Study characteristics and significant results, ordered by intervention and control devices.
    Rt Cgm Dexcom G4 Platinum, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rt-cgm dexcom g4 platinum/product/Dexcom Inc
    Average 90 stars, based on 1 article reviews
    rt-cgm dexcom g4 platinum - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Main findings and highlights resulted by the systematic review

    Journal: Reviews in Endocrine & Metabolic Disorders

    Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

    doi: 10.1007/s11154-024-09903-y

    Figure Lengend Snippet: Main findings and highlights resulted by the systematic review

    Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

    Techniques: Control

    Rt-CGM/FGM in GSDs: population features, devices and study design

    Journal: Reviews in Endocrine & Metabolic Disorders

    Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

    doi: 10.1007/s11154-024-09903-y

    Figure Lengend Snippet: Rt-CGM/FGM in GSDs: population features, devices and study design

    Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

    Techniques: Control

    Rt-CGM/FGM in CH: population features, devices and study design

    Journal: Reviews in Endocrine & Metabolic Disorders

    Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

    doi: 10.1007/s11154-024-09903-y

    Figure Lengend Snippet: Rt-CGM/FGM in CH: population features, devices and study design

    Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

    Techniques: Biomarker Discovery, Control

    Summary Results of Base Case Analysis

    Journal: ClinicoEconomics and Outcomes Research: CEOR

    Article Title: Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada

    doi: 10.2147/CEOR.S304395

    Figure Lengend Snippet: Summary Results of Base Case Analysis

    Article Snippet: The DIAMOND trial was a randomized controlled trial conducted across multiple sites in North America, in which a total of 158 adults aged ≥25 years with T1D and treated with multiple daily injections of insulin for at least 1 year previously were randomly allocated (in a 2:1 ratio) to either RT-CGM (using the Dexcom G4 platinum system) or usual care with SMBG.

    Techniques:

    Study characteristics and significant results, ordered by intervention and control devices.

    Journal: Therapeutic Advances in Endocrinology and Metabolism

    Article Title: The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials

    doi: 10.1177/2042018819871903

    Figure Lengend Snippet: Study characteristics and significant results, ordered by intervention and control devices.

    Article Snippet: Polonsky et al. Further findings from DIAMOND , 158 adults (MDI) , RT-CGM (Dexcom G4 Platinum) ( n = 105) , SMBG (Bayer Contour Next USB; n = 53) , 6 , NI , NI , NI , ↑ Hypo confidence ↓ Diabetes distress ↑ Satisfaction .

    Techniques: Control